Aptose Biosciences (NASDAQ:APTO) Coverage Initiated at StockNews.com

Analysts at StockNews.com started coverage on shares of Aptose Biosciences (NASDAQ:APTO) (TSE:APS) in a note issued to investors on Monday. The brokerage set a “hold” rating on the biotechnology company’s stock.

A number of other brokerages also recently weighed in on APTO. HC Wainwright reiterated a “buy” rating and issued a $7.00 price objective on shares of Aptose Biosciences in a research report on Friday, June 14th. Piper Sandler restated an “overweight” rating and set a $5.00 price target on shares of Aptose Biosciences in a research report on Wednesday, April 3rd. Finally, Canaccord Genuity Group reduced their price target on shares of Aptose Biosciences from $15.00 to $6.00 and set a “buy” rating for the company in a research report on Thursday, May 16th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $14.83.

Aptose Biosciences Stock Performance

NASDAQ:APTO opened at $0.71 on Monday. Aptose Biosciences has a one year low of $0.70 and a one year high of $5.10. The firm has a market cap of $12.86 million, a price-to-earnings ratio of -0.11 and a beta of 1.26. The firm’s fifty day moving average is $0.99 and its two-hundred day moving average is $1.53.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings data on Tuesday, May 14th. The biotechnology company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.09. As a group, equities research analysts predict that Aptose Biosciences will post -2.67 earnings per share for the current fiscal year.

Institutional Trading of Aptose Biosciences

An institutional investor recently bought a new position in Aptose Biosciences stock. Texas Capital Bank Wealth Management Services Inc purchased a new stake in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 12,448 shares of the biotechnology company’s stock, valued at approximately $32,000. Texas Capital Bank Wealth Management Services Inc owned 0.16% of Aptose Biosciences at the end of the most recent reporting period. 26.62% of the stock is owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.